请输入您要查询的百科知识：

　

词条 Anti-diabetic medication
释义

  1. Insulin

  2. Sensitizers

     Biguanides  Thiazolidinediones  Lyn kinase activators 

  3. Secretagogues

     Sulfonylureas  Nonsulfonylurea secretagogues  Meglitinides 

  4. Alpha-glucosidase inhibitors

  5. Peptide analogs

     Injectable incretin mimetics   Injectable glucagon-like peptide analogs and agonists  Gastric inhibitory peptide analogs  Dipeptidyl peptidase-4 inhibitors  Injectable amylin analogues 

  6. Glycosurics

  7. Comparison

  8. Generic

  9. References

  10. Further reading

{{Use mdy dates|date=September 2011}}

Drugs used in diabetes treat diabetes mellitus by lowering the glucose level in the blood. With the exceptions of insulin, exenatide, liraglutide and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.

Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in type 1, which must be injected.

Diabetes mellitus type 2 is a disease of insulin resistance by cells. Type 2 diabetes mellitus is the most common type of diabetes. Treatments include (1) agents that increase the amount of insulin secreted by the pancreas, (2) agents that increase the sensitivity of target organs to insulin, and (3) agents that decrease the rate at which glucose is absorbed from the gastrointestinal tract.

Several groups of drugs, mostly given by mouth, are effective in type 2, often in combination. The therapeutic combination in type 2 may include insulin, not necessarily because oral agents have failed completely, but in search of a desired combination of effects. The great advantage of injected insulin in type 2 is that a well-educated patient can adjust the dose, or even take additional doses, when blood glucose levels measured by the patient, usually with a simple meter, as needed by the measured amount of sugar in the blood.

{{TOC limit|3}}

Insulin

{{Main|insulin (medication)}}

Insulin is usually given subcutaneously, either by injections or by an insulin pump. Research of other routes of administration is underway. In acute-care settings, insulin may also be given intravenously. In general, there are three types of insulin, characterized by the rate which they are metabolized by the body. They are rapid acting insulins, intermediate acting insulins and long acting insulins.[1]

Examples of rapid acting insulins include

  • Regular insulin (Humulin R, Novolin R)
  • Insulin lispro (Humalog)
  • Insulin aspart (Novolog)
  • Insulin glulisine (Apidra)
  • Prompt insulin zinc (Semilente, Slightly slower acting)

Examples of intermediate acting insulins include

  • Isophane insulin, neutral protamine Hagedorn (NPH) (Humulin N, Novolin N)
  • Insulin zinc (Lente)

Examples of long acting insulins include

  • Extended insulin zinc insulin (Ultralente)
  • Insulin glargine (Lantus)
  • Insulin detemir (Levemir)
  • Insulin degludec (Tresiba)

Most anti-diabetic agents are contraindicated in pregnancy, in which insulin is preferred.[2]

Sensitizers

Insulin sensitizers address the core problem in type 2 diabetes – insulin resistance.

Biguanides

{{Main|Biguanide}}

Biguanides reduce hepatic glucose output and increase uptake of glucose by the periphery, including skeletal muscle. Although it must be used with caution in patients with impaired liver or kidney function, metformin, a biguanide, has become the most commonly used agent for type 2 diabetes in children and teenagers. Among common diabetic drugs, metformin is the only widely used oral drug that does not cause weight gain.

Typical reduction in glycated hemoglobin (A1C) values for metformin is 1.5–2.0%

  • Metformin (Glucophage) may be the best choice for patients who also have heart failure,[2] but it should be temporarily discontinued before any radiographic procedure involving intravenous iodinated contrast, as patients are at an increased risk of lactic acidosis.
  • Phenformin (DBI) was used from 1960s through 1980s, but was withdrawn due to lactic acidosis risk.[3]
  • Buformin also was withdrawn due to lactic acidosis risk.[4]

Metformin is usually the first-line medication used for treatment of type 2 diabetes. In general, it is prescribed at initial diagnosis in conjunction with exercise and weight loss, as opposed to in the past, where it was prescribed after diet and exercise had failed. There is an immediate release as well as an extended-release formulation, typically reserved for patients experiencing gastrointestinal side-effects. It is also available in combination with other oral diabetic medications.

Thiazolidinediones

{{Main|Thiazolidinedione}}

Thiazolidinediones (TZDs), also known as "glitazones," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of genes regulating glucose and fat metabolism. These PPARs act on peroxysome proliferator responsive elements (PPRE).[5] The PPREs influence insulin-sensitive genes, which enhance production of mRNAs of insulin-dependent enzymes. The final result is better use of glucose by the cells.

Typical reductions in glycated hemoglobin (A1C) values are 1.5–2.0%. Some examples are:

  • rosiglitazone (Avandia): the European Medicines Agency recommended in September 2010 that it be suspended from the EU market due to elevated cardiovascular risks.[6]
  • pioglitazone (Actos)
  • troglitazone (Rezulin): used in 1990s, withdrawn due to hepatitis and liver damage risk[7]

Multiple retrospective studies have resulted in a concern about rosiglitazone's safety, although it is established that the group, as a whole, has beneficial effects on diabetes. The greatest concern is an increase in the number of severe cardiac events in patients taking it. The ADOPT study showed that initial therapy with drugs of this type may prevent the progression of disease,[8] as did the DREAM trial.[9]

Concerns about the safety of rosiglitazone arose when a retrospective meta-analysis was published in the New England Journal of Medicine.[10] There have been a significant number of publications since then, and a Food and Drug Administration panel[11] voted, with some controversy, 20:3 that available studies "supported a signal of harm", but voted 22:1 to keep the drug on the market. The meta-analysis was not supported by an interim analysis of the trial designed to evaluate the issue, and several other reports have failed to conclude the controversy. This weak evidence for adverse effects has reduced the use of rosiglitazone, despite its important and sustained effects on glycemic control.[12] Safety studies are continuing.

In contrast, at least one large prospective study, PROactive 05, has shown that pioglitazone may decrease the overall incidence of cardiac events in people with type 2 diabetes who have already had a heart attack.[13]

Lyn kinase activators

The LYN kinase activator tolimidone has been reported to potentiate insulin signaling in a manner that is distinct from the glitazones.[14] The compound has demonstrated positive results in a Phase 2a clinical study involving 130 diabetic subjects.[15]

Secretagogues

Secretagogues are drugs that increase insulin output from the pancreas.

Sulfonylureas

{{unreferenced section|date=January 2016}}{{Main|Sulfonylurea}}

Sulfonylureas were the first widely used oral anti-hyperglycemic medications. They are insulin secretagogues, triggering insulin release by inhibiting the KATP channel of the pancreatic beta cells. Eight types of these pills have been marketed in North America, but not all remain available. The "second-generation" drugs are now more commonly used. They are more effective than first-generation drugs and have fewer side-effects. All may cause weight gain.

Sulfonylureas bind strongly to plasma proteins. Sulfonylureas are useful only in type 2 diabetes, as they work by stimulating endogenous release of insulin. They work best with patients over 40 years old who have had diabetes mellitus for under ten years. They cannot be used with type 1 diabetes, or diabetes of pregnancy. They can be safely used with metformin or glitazones. The primary side-effect is hypoglycemia.

Typical reductions in glycated hemoglobin (A1C) values for second-generation sulfonylureas are 1.0–2.0%.

  • First-generation agents
    • tolbutamide
    • acetohexamide
    • tolazamide
    • chlorpropamide
  • Second-generation agents
    • glipizide
    • glyburide or glibenclamide
    • glimepiride
    • gliclazide
    • glyclopyramide
    • gliquidone

Nonsulfonylurea secretagogues

Meglitinides

{{Main|Meglitinide}}Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues." They act on the same potassium channels as sulfonylureas, but at a different binding site.[16] By closing the potassium channels of the pancreatic beta cells, they open the calcium channels, thereby enhancing insulin secretion.[17]

They are taken with or shortly before meals to boost the insulin response to each meal. If a meal is skipped, the medication is also skipped.

Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.

  • repaglinide
  • nateglinide

Adverse reactions include weight gain and hypoglycemia.

Alpha-glucosidase inhibitors

{{unreferenced section|date=January 2016}}{{Main|Alpha-glucosidase inhibitor}}

Alpha-glucosidase inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, so that glucose from the starch of a meal enters the bloodstream more slowly, and can be matched more effectively by an impaired insulin response or sensitivity. These agents are effective by themselves only in the earliest stages of impaired glucose tolerance, but can be helpful in combination with other agents in type 2 diabetes.

Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.

  • miglitol
  • acarbose
  • voglibose

These medications are rarely used in the United States because of the severity of their side-effects (flatulence and bloating). They are more commonly prescribed in Europe. They do have the potential to cause weight loss by lowering the amount of sugar metabolized.

Peptide analogs

{{refimprove section|date=January 2016}}

Injectable incretin mimetics

Incretins are insulin secretagogues. The two main candidate molecules that fulfill criteria for being an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (glucose-dependent insulinotropic peptide, GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

Injectable glucagon-like peptide analogs and agonists

Glucagon-like peptide (GLP) agonists bind to a membrane GLP receptor.[17] As a consequence, insulin release from the pancreatic beta cells is increased. Endogenous GLP has a half-life of only a few minutes, thus an analogue of GLP would not be practical.

  • Exenatide (also Exendin-4, marketed as Byetta) is the first GLP-1 agonist approved for the treatment of type 2 diabetes. Exenatide is not an analogue of GLP but rather a GLP agonist.[18][19] Exenatide has only 53% homology with GLP, which increases its resistance to degradation by DPP-4 and extends its half-life.[20] Typical reductions in A1C values are 0.5–1.0%.
  • Liraglutide, a once-daily human analogue (97% homology), has been developed by Novo Nordisk under the brand name Victoza. The product was approved by the European Medicines Agency (EMEA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.[21][22][23][24][25][26]
  • Taspoglutide is presently in Phase III clinical trials with Hoffman-La Roche.
  • Lixisenatide (Lyxumia) Sanofi Aventis
  • Semaglutide (Ozempic)

These agents may also cause a decrease in gastric motility, responsible for the common side-effect of nausea, and is probably the mechanism by which weight loss occurs.

Gastric inhibitory peptide analogs

Dipeptidyl peptidase-4 inhibitors

{{Main|Dipeptidyl peptidase-4 inhibitors}}

GLP-1 analogs resulted in weight loss and had more gastrointestinal side-effects, while in general DPP-4 inhibitors were weight-neutral and increased risk for infection and headache, but both classes appear to present an alternative to other antidiabetic drugs. However, weight gain and/or hypoglycemia have been observed when DPP-4 inhibitors were used with sulfonylureas; effect on long-term health and morbidity rates are still unknown.[27]

Dipeptidyl peptidase-4 (DPP-4) inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by dipeptidyl peptidase-4.

Examples are:

  • vildagliptin (Galvus) EU Approved 2008
  • sitagliptin (Januvia) FDA approved Oct 2006
  • saxagliptin (Onglyza) FDA Approved July 2009
  • linagliptin (Tradjenta) FDA Approved May 2, 2011
  • alogliptin
  • septagliptin
  • Teneligliptin
  • Zemiglo
DPP-4 inhibitors lowered hemoglobin A1C values by 0.74%, comparable to other antidiabetic drugs.[28]

A result in one RCT comprising 206 patients aged 65 or older (mean baseline HgbA1c of 7.8%) receiving either 50 or 100 mg/d of Sitagliptin was shown to reduce HbA1c by 0.7% (combined result of both doses).[29] A combined result of 5 RCTs enlisting a total of 279 patients aged 65 or older (mean baseline HbA1c of 8%) receiving 5 mg/d of Saxagliptin was shown to reduce HbA1c by 0.73%.[30] A combined result of 5 RCTs enlisting a total of 238 patients aged 65 or older (mean baseline HbA1c of 8.6%) receiving 100 mg/d of Vildagliptin was shown to reduce HbA1c by 1.2%.[31] Another set of 6 combined RCTs involving Alogliptin (approved by FDA in 2013) was shown to reduce HbA1c by 0.73% in 455 patients aged 65 or older who received 12.5 or 25 mg/d of the medication.[32]

Injectable amylin analogues

{{unreferenced section|date=January 2016}}

Amylin agonist analogues slow gastric emptying and suppress glucagon. They have all the incretins actions except stimulation of insulin secretion. {{As of|2007}}, pramlintide is the only clinically available amylin analogue. Like insulin, it is administered by subcutaneous injection. The most frequent and severe adverse effect of pramlintide is nausea, which occurs mostly at the beginning of treatment and gradually reduces. Typical reductions in A1C values are 0.5–1.0%.

Glycosurics

{{Main|Gliflozin}}SGLT-2 inhibitors block the re-uptake of glucose in the renal tubules, promoting loss of glucose in the urine. This causes both mild weight loss, and a mild reduction in blood sugar levels with little risk of hypoglycemia.[33] Oral preparations may be available alone or in combination with other agents.[34]

Examples include:

  • Dapagliflozin
  • Canagliflozin
  • Empagliflozin

The side effects of SGLT-2 inhibitors are derived directly from their mechanism of action; these include an increased risk of: ketoacidosis, urinary tract infections, candidal vulvovaginitis, and hypoglycemia.[35]

Comparison

The following table compares some common anti-diabetic agents, generalizing classes, although there may be substantial variation in individual drugs of each class. When the table makes a comparison such as "lower risk" or "more convenient" the comparison is with the other drugs on the table.

Comparison of anti-diabetic medication[36][37]
agent[37] mechanism[38] advantages[37] disadvantages[37]
Sulfonylurea (glyburide, glimepiride, glipizide) Stimulating insulin release by pancreatic beta cells by inhibiting the KATP channel
  • Inexpensive
  • Fast onset of action
  • No effect on blood pressure
  • No effect on low-density lipoprotein
  • lower risk of gastrointestinal problems than with metformin
  • more convenient dosing
  • Causes an average of 5–10 pounds weight gain
  • Increased risk of hypoglycemia
  • Glyburide has increases risk of hypoglycemia slightly more as compared with glimepiride and glipizide
Metformin Acts on the liver to reduce gluconeogenesis and causes a decrease in insulin resistance via increasing AMPK signalling.
  • Not associated with weight gain
  • Low risk of hypoglycemia as compared to alternatives
  • Good effect on LDL cholesterol
  • Decreases triglycerides
  • No effect on blood pressure
  • Inexpensive
  • Increased risk of gastrointestinal problems
  • Due to risk of potentially fatal lactic acidosis, contraindicated for people in shock; with acute or chronic, moderate or severe kidney disease or at risk for impaired kidney function from intravenous dye; and with acute or chronic metabolic acidosis
  • Risk of lactic acidosis also is increased for people with unstable or acute heart failure, liver disease, or alcoholism, or who are recovering from major surgery
  • Increased risk of Vitamin B12 deficiency[38]
  • Less convenient dosing
  • Metallic taste[38]
Alpha-glucosidase inhibitor (acarbose, miglitol, voglibose) Reduces glucose absorbance by acting on small intestine to cause decrease in production of enzymes needed to digest carbohydrates
  • Slightly decreased risk of hypoglycemia as compared to sulfonylurea
  • Not associated with weight gain
  • Decreases triglycerides
  • No effect on cholesterol
  • Less effective than most other diabetes pills in decreasing glycated hemoglobin
  • Increased risk of GI problems than other diabetes pills except metformin
  • Inconvenient dosing
  • Expensive
Thiazolidinediones (Pioglitazone, Rosiglitazone) Reduce insulin resistance by activating PPAR-γ in fat and muscle
  • Lower risk of hypoglycemia
  • Slight increase in high-density lipoprotein
  • Actos linked to decreased triglycerides
  • Convenient dosing
  • Increased risk of heart failure
  • Causes an average of 5–10 pounds weight gain
  • Associated with higher risk of edema
  • Associated with higher risk of anemia
  • Increases low-density lipoprotein
  • Avandia linked to increased triglycerides and risk of heart attack
  • Actos linked to increased risk of bladder cancer
  • Slower onset of action
  • Requires monitoring for hepatoxicity
  • Associated with increased risk of limb fractures
  • Expensive

Generic

Many anti-diabetes drugs are available as generics. These include:[39]

  • Sulfonylureas – glimepiride, glipizide, glyburide
  • Biguanides – metformin
  • Thiazolidinediones (Tzd) – pioglitazone, Actos generic
  • Alpha-glucosidase inhibitors – Acarbose
  • Meglitinides – nateglinide
  • Combination of sulfonylureas plus metformin – known by generic names of the two drugs

No generics are available for dipeptidyl peptidase-4 inhibitors (Januvia, Onglyza) and other combinations.

References

1. ^Diabetes Mellitus, Alvin C. Powers in Harrison's Principles of Internal Medicine, 18th edition, Chapter 345, {{ISBN|978-0071748896}}
2. ^{{cite journal |pmid=17761999 |doi=10.1136/bmj.39314.620174.80 |year=2007 |author1=Eurich |first2=FA |first3=DF |first4=SR |first5=RT |first6=J |first7=JA |title=Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review |volume=335 |issue=7618 |pages=497 |pmc=1971204 |journal=BMJ (Clinical Research Ed.) |last2=McAlister |last3=Blackburn |last4=Majumdar |last5=Tsuyuki |last6=Varney |last7=Johnson}}
3. ^{{cite journal |pmid=16567854 |url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=16567854 |doi=10.2337/diacare.29.04.06.dc06-0012 |year=2006 |author1=Fimognari |first2=R |first3=RA |title=Phenformin-induced lactic acidosis in an older diabetic patient: a recurrent drama (phenformin and lactic acidosis) |volume=29 |issue=4 |pages=950–1 |journal=Diabetes Care |last2=Pastorelli |last3=Incalzi |deadurl=no |archiveurl=https://archive.is/20121209052027/http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=16567854 |archivedate=December 9, 2012 |df=mdy-all }}
4. ^{{cite journal |pmid=7202882 |doi=10.1007/BF01789112 |year=1981 |author1=Verdonck |first2=B |first3=AN |first4=G |first5=RA |title=Buformin concentrations in a case of fatal lactic acidosis |volume=20 |issue=1 |pages=45–6 |journal=Diabetologia |last2=Sangster |last3=Van Heijst |last4=De Groot |last5=Maes}}
5. ^{{cite web|url=http://www.healthvalue.net/diabetesinsulinPPAR.html|title=diabetesinsulinPPAR|author=|date=|website=www.healthvalue.net|accessdate=May 6, 2018|deadurl=no|archiveurl=https://web.archive.org/web/20160303204348/http://www.healthvalue.net/diabetesinsulinPPAR.html|archivedate=March 3, 2016|df=mdy-all}}
6. ^European Medicines Agency, "European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim" {{webarchive|url=https://web.archive.org/web/20140203052646/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2010%2F09%2Fnews_detail_001119.jsp&mid=WC0b01ac058004d5c1&jsenabled=true |date=February 3, 2014 }}, EMA, 23 September 2009
7. ^{{cite news | last = Hinterthuer | first = Adam | title = Retired Drugs: Failed Blockbusters, Homicidal Tampering, Fatal Oversights | publisher = Wired News | url = https://www.wired.com/medtech/drugs/multimedia/2008/10/gallery_retired_drugs?slide=6&slideView=6 | accessdate = 2009-06-21 | date = October 1, 2008 | deadurl = no | archiveurl = https://web.archive.org/web/20081204050525/http://www.wired.com/medtech/drugs/multimedia/2008/10/gallery_retired_drugs?slide=6&slideView=6 | archivedate = December 4, 2008 | df = mdy-all }}
8. ^{{cite web | last = Haffner | first = Steven M. | title = Expert Column – A Diabetes Outcome Progression Trial (ADOPT) | publisher=Medscape | year = 2007 | url = http://www.medscape.com/viewarticle/552484 | accessdate = 2007-09-21}}
9. ^{{cite web | last = Gagnon | first = Louise | title = DREAM: Rosiglitazone Effective in Preventing Diabetes | publisher = Medscape | year = 2007 | url = http://www.medscape.com/viewarticle/546503 | accessdate = 2007-09-21 | deadurl = no | archiveurl = https://web.archive.org/web/20081202225351/http://www.medscape.com/viewarticle/546503 | archivedate = December 2, 2008 | df = mdy-all }}
10. ^{{cite journal |doi=10.1056/NEJMoa072761 |pmid=17517853 |laysummary=http://www.msnbc.msn.com/id/18783816 |laysource=Associated Press |laydate=May 21, 2007 |year=2007 |author1=Nissen |first2=K |title=Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes |volume=356 |issue=24 |pages=2457–71 |journal=The New England Journal of Medicine |last2=Wolski}}
11. ^{{cite web | last = Wood | first = Shelley | title = FDA Advisory Panels Acknowledge Signal of Risk With Rosiglitazone, but Stop Short of Recommending Its Withdrawal | publisher = Heartwire | date = 2007-07-31 | url = http://www.medscape.com/viewarticle/560709 | accessdate = 2007-09-21 | deadurl = no | archiveurl = https://web.archive.org/web/20140318013618/http://www.medscape.com/viewarticle/560709 | archivedate = March 18, 2014 | df = mdy-all }}
12. ^{{cite journal |pmid=18613801 |doi=10.1517/14740338.7.4.367 |year=2008 |author1=Ajjan |first2=PJ |title=The cardiovascular safety of rosiglitazone |volume=7 |issue=4 |pages=367–76 |journal=Expert Opinion on Drug Safety |last2=Grant}}
13. ^{{cite journal |pmid=17466227 |doi=10.1016/j.jacc.2006.12.048 |year=2007 |author1=Erdmann |first2=JA |first3=B |first4=M |first5=IK |first6=AM |first7=Investigators |title=The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study |volume=49 |issue=17 |pages=1772–80 |journal=Journal of the American College of Cardiology |last2=Dormandy |last3=Charbonnel |last4=Massi-Benedetti |last5=Moules |last6=Skene |last7=Proactive}}
14. ^{{cite journal | vauthors = Müller G, Wied S, Frick W | title = Cross talk of pp125(FAK) and pp59(Lyn) non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes | journal = Molecular and Cellular Biology | volume = 20 | issue = 13 | pages = 4708–4723 | date = Jul 2000 | pmid = 10848597 | pmc = 85892 | doi = 10.1128/mcb.20.13.4708-4723.2000 }}
15. ^{{cite web|url=http://www.businesswire.com/news/home/20160613005028/en/Melior-Pharmaceuticals-Announces-Positive-Phase-2A-Results|title=Melior Pharmaceuticals Announces Positive Phase 2A Results in Type 2 Diabetes Study|author=|date=|website=businesswire.com|accessdate=May 6, 2018|deadurl=no|archiveurl=https://web.archive.org/web/20170812162052/http://www.businesswire.com/news/home/20160613005028/en/Melior-Pharmaceuticals-Announces-Positive-Phase-2A-Results|archivedate=August 12, 2017|df=mdy-all}}
16. ^{{cite journal |pmid=15647714 |pmc=1474831 |year=2004 |author1=Rendell |title=Advances in diabetes for the millennium: drug therapy of type 2 diabetes |volume=6 |issue=3 Suppl |pages=9 |journal=MedGenMed : Medscape General Medicine}}
17. ^1 {{cite web | url = http://www.healthvalue.net/diabetespancreasbeta.html | title = Helping the pancreas produce insulin | accessdate = 2007-09-21 | publisher=HealthValue| archiveurl= https://web.archive.org/web/20070927043729/http://www.healthvalue.net/diabetespancreasbeta.html| archivedate= September 27, 2007 | deadurl= no}}
18. ^{{cite journal |pmid=16722815 |doi=10.1517/14656566.7.8.1055 |year=2006 |author1=Briones |first2=M |title=Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus |volume=7 |issue=8 |pages=1055–64 |journal=Expert Opinion on Pharmacotherapy |last2=Bajaj}}
19. ^{{cite journal |pmid=17109672 |doi=10.1111/j.1742-1241.2006.01196.x |year=2006 |author1=Gallwitz |title=Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data |volume=60 |issue=12 |pages=1654–61 |journal=International Journal of Clinical Practice}}
20. ^{{cite journal |pmid=17428109 |doi=10.2165/00003495-200767060-00008 |year=2007 |author1=Cvetković |first2=GL |title=Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea) |volume=67 |issue=6 |pages=935–54 |journal=Drugs |last2=Plosker}}
21. ^{{cite web |url=https://www.drugs.com/nda/liraglutide_080530.html |title=Archived copy |accessdate=2018-01-23 |deadurl=no |archiveurl=https://web.archive.org/web/20171215054200/https://www.drugs.com/nda/liraglutide_080530.html |archivedate=December 15, 2017 |df=mdy-all }} May 2008
22. ^{{cite web |url=http://www.medicalnewstoday.com/articles/74913.php |title=Archived copy |accessdate=2010-02-09 |deadurl=no |archiveurl=https://web.archive.org/web/20100723042509/http://www.medicalnewstoday.com/articles/74913.php |archivedate=July 23, 2010 |df=mdy-all }} "Liraglutide Provides Significantly Better Glucose Control Than Insulin Glargine In Phase 3 Study" June 2007
23. ^{{cite web |url=http://www.medicalnewstoday.com/articles/110349.php |title=Archived copy |accessdate=2010-02-09 |deadurl=no |archiveurl=https://web.archive.org/web/20090205233559/http://www.medicalnewstoday.com/articles/110349.php |archivedate=February 5, 2009 |df=mdy-all }} "Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, And Blood Pressure In Patients With Type 2 Diabetes" June 2008
24. ^{{cite web |url=http://www.drugdevelopment-technology.com/projects/liraglutide/ |title=Archived copy |accessdate=2010-02-09 |deadurl=no |archiveurl=https://web.archive.org/web/20100618110150/http://www.drugdevelopment-technology.com/projects/liraglutide/ |archivedate=June 18, 2010 |df=mdy-all }}
25. ^{{cite web|url=http://www.novonordisk.com/science/about_rd/quarterly_rd_update.asp |title=Archived copy |accessdate=2010-02-09 |deadurl=yes |archiveurl=https://web.archive.org/web/20100109101501/http://www.novonordisk.com/science/about_rd/quarterly_rd_update.asp |archivedate=January 9, 2010 }} Oct 2008 Inc results of LEAD 6 extension
26. ^{{cite web |url=http://money.cnn.com/news/newsfeeds/articles/marketwire/0580389.htm |title=Archived copy |accessdate=2010-02-09 |deadurl=no |archiveurl=https://web.archive.org/web/20100129215943/http://money.cnn.com/news/newsfeeds/articles/marketwire/0580389.htm |archivedate=January 29, 2010 |df=mdy-all }} January 2009
27. ^{{Cite journal |author=National Prescribing Service |journal=RADAR |title=Dipeptidyl peptidase-4 inhibitors ('gliptins') for type 2 diabetes mellitus |date=August 1, 2010 |url=http://www.nps.org.au/health_professionals/publications/nps_radar/2008/august_2008/gliptins }}{{dead link|date=January 2018 |bot=InternetArchiveBot |fix-attempted=yes }}
28. ^{{cite journal |vauthors=Amori RE, Lau J, Pittas AG |title=Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis |journal=JAMA |volume=298 |issue=2 |pages=194–206 |year=2007 |pmid=17622601 |doi=10.1001/jama.298.2.194 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=17622601}}
29. ^{{cite journal|last=Barzilei|first=N|author2=Mahoney EM |author3=Guo H |title=Sitagliptin is well tolerated and leads to rapid improvement in blood glucose in the first days of monotherapy in patients aged 65 years and older with T2DM|journal=Diabetes|year=2009|volume=58|pages=587}}
30. ^{{cite journal|last=Doucet|first=J|author2=Chacra, A|author3=Maheux, P|author4=Lu, J|author5=Harris, S|author6=Rosenstock, J|title=Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus|journal=Current Medical Research and Opinion|date=April 2011|volume=27|issue=4|pages=863–9|pmid=21323504|doi=10.1185/03007995.2011.554532}}
31. ^{{cite journal|last=Pratley|first=RE|author2=Rosenstock, J|author3=Pi-Sunyer, FX|author4=Banerji, MA|author5=Schweizer, A|author6=Couturier, A|author7=Dejager, S|title=Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy|journal=Diabetes Care|date=December 2007|volume=30|issue=12|pages=3017–22|pmid=17878242|doi=10.2337/dc07-1188}}
32. ^{{cite journal|last=Pratley|first=RE|author2=McCall, T|author3=Fleck, PR|author4=Wilson, CA|author5=Mekki, Q|title=Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies|journal=Journal of the American Geriatrics Society|date=November 2009|volume=57|issue=11|pages=2011–9|pmid=19793357|doi=10.1111/j.1532-5415.2009.02484.x}}
33. ^{{cite journal|last=Dietrich|first=E|author2=Powell, J|author3=Taylor, JR|title=Canagliflozin: a novel treatment option for type 2 diabetes.|journal=Drug Design, Development and Therapy|date=November 2013|volume=7|pages=1399–1408|pmid=24285921|doi=10.2147/DDDT.S48937|pmc=3840773}}
34. ^{{Cite web|url=https://www.fda.gov/Drugs/DrugSafety/ucm446852.htm|title=Drug Safety and Availability - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors|last=Research|first=Center for Drug Evaluation and|website=www.fda.gov|language=en|access-date=2017-08-26|deadurl=no|archiveurl=https://web.archive.org/web/20161129094121/http://www.fda.gov/Drugs/DrugSafety/ucm446852.htm|archivedate=November 29, 2016|df=mdy-all}}
35. ^{{Cite news|url=http://www.diabetes.co.uk/diabetes-medication/sglt2-inhibitors.html|title=SGLT2 Inhibitors (Gliflozins) – Drugs, Suitability, Benefits & Side Effects|access-date=2017-08-26|deadurl=no|archiveurl=https://web.archive.org/web/20170827050028/http://www.diabetes.co.uk/diabetes-medication/sglt2-inhibitors.html|archivedate=August 27, 2017|df=mdy-all}}
36. ^{{Cite journal | last1 = Cambon-Thomsen | first1 = A. | last2 = Rial-Sebbag | first2 = E. | last3 = Knoppers | first3 = B. M. | title = Trends in ethical and legal frameworks for the use of human biobanks | journal = European Respiratory Journal | volume = 30 | issue = 2 | pages = 373–382 | year = 2007 | pmid = 17666560 | doi = 10.1183/09031936.00165006| url = http://www.hal.inserm.fr/inserm-00168261 }} adapted from table 2, which includes a list of issues
37. ^1 2 3 {{Cite journal |author1 = Consumer Reports Health Best Buy Drugs |author1-link = Consumer Reports |title = The Oral Diabetes Drugs: Treating Type 2 Diabetes |publisher = Consumer Reports |journal = Best Buy Drugs |page = 20 |url = http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/DiabetesUpdate-FINAL-Feb09.pdf |accessdate = September 18, 2012 |deadurl = no |archiveurl = https://web.archive.org/web/20130227145458/http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/DiabetesUpdate-FINAL-Feb09.pdf |archivedate = February 27, 2013 |df = mdy-all }}, which is citing*{{cite journal|title=Oral Diabetes Medications for Adults With Type 2 Diabetes. An Update|journal=Comparative Effectiveness Review|date=March 2011|volume=number 27|issue=AHRQ Pub. No. 11–EHC038–1|url=http://effectivehealthcare.ahrq.gov/ehc/products/155/645/Oral%20Diabetes_ExSumm%20%282%29.pdf|accessdate=28 November 2012|author=Agency for Healthcare Research and Quality|deadurl=yes|archiveurl=https://web.archive.org/web/20130927121129/http://effectivehealthcare.ahrq.gov/ehc/products/155/645/Oral%20Diabetes_ExSumm%20%282%29.pdf|archivedate=September 27, 2013|df=mdy-all}}*{{Cite journal | last1 = Bennett | first1 = W. L. | last2 = Maruthur | first2 = N. M. | last3 = Singh | first3 = S. | last4 = Segal | first4 = J. B. | last5 = Wilson | first5 = L. M. | last6 = Chatterjee | first6 = R. | last7 = Marinopoulos | first7 = S. S. | last8 = Puhan | first8 = M. A. | last9 = Ranasinghe | first9 = P. | last10 = Block | first10 = L. | last11 = Nicholson | first11 = W. K. | last12 = Hutfless | first12 = S. | last13 = Bass | first13 = E. B. | last14 = Bolen | first14 = S. | title = Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations | journal = Annals of Internal Medicine | volume = 154 | issue = 9 | pages = 602–613 | year = 2011 | doi = 10.7326/0003-4819-154-9-201105030-00336 | pmid = 21403054 | pmc =3733115 }}
38. ^1 2 3 Table entries taken from page 185 in: {{cite book |author1=Elizabeth D Agabegi |author2=Agabegi, Steven S. |title=Step-Up to Medicine (Step-Up Series) |publisher=Lippincott Williams & Wilkins |location=Hagerstwon, MD |year=2008 |isbn=978-0-7817-7153-5 |oclc= }}
39. ^{{cite web |url=http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/DiabetesUpdate-FINAL-Feb09.pdf |title=The Oral Diabetes Drugs Treating Type 2 Diabetes Comparing Effectiveness, Safety, and Price |accessdate=July 17, 2013 |deadurl=no |archiveurl=https://web.archive.org/web/20130615083100/http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/DiabetesUpdate-FINAL-Feb09.pdf |archivedate=June 15, 2013 |df=mdy-all }}

Further reading

  • {{cite book |author=Lebovitz, Harold E. |title=Therapy For Diabetes Mellitus and Related Disorders |publisher=American Diabetes Association |location=Alexandria, VA |year=2004 |edition=4th |isbn=978-1-58040-187-6 |oclc= }}
  • {{cite book |author1=Adams, Michael Ian |author2=Holland, Norman Norwood |title=Core Concepts in Pharmacology |publisher=Prentice Hall |location=Englewood Cliffs, NJ |year=2003 |isbn=978-0-13-089329-1 |oclc= }}
{{Oral hypoglycemics}}{{Major Drug Groups}}{{Diabetes}}{{DEFAULTSORT:Anti-Diabetic Drug}}

1 : Anti-diabetic drugs
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/21 0:34:54